FLT3 and acute myeloid leukemia: When combined with standard 7+3 induction chemotherapy in newly diagnosed FLT3-mutated AML, crenolanib produced high composite remission rates—up to 85%—and encouraging early survival outcomes, with manageable gastrointestinal and hepatic toxicities (NCT02283177) [78].